NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for serious central nervous system disorders, including suicidal depression, PTSD, chronic pain, and schizophrenia. The company operates through NeuroRx, its research and development subsidiary, and HOPE Therapeutics, its clinical care delivery subsidiary, which is intended to own and operate psychiatric treatment clinics.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage development of NMDA-targeted therapies such as NRX-101 and NRX-100.
Ownership and operation of psychiatric clinics through HOPE Therapeutics.
Treatment programs using TMS, ketamine, and related neuromodulatory approaches.
Ancillary psychiatric care services and patient monitoring tools.
Tuotteet
Raportoitu · osuus liikevaihdosta- Therapy69,7 %
- Procedures30,3 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
NRx sells to physicians, clinics, and healthcare organizations that treat patients with severe psychiatric and neurologic conditions. Its drug-development business is aimed at prescribers and future commercial buyers, while HOPE serves patients directly through clinic-based care. The core end markets are treatment-resistant depression, suicidal depression, PTSD, chronic pain, and schizophrenia.
They prescribe NRX-101/NRX-100 and use TMS-based protocols for severe depression and related disorders.
They buy HOPE clinic services, treatment workflows, and neuromodulation-based care delivery.
They receive clinic-based treatment for suicidal depression, PTSD, chronic pain, and schizophrenia.
They represent the eventual commercial channel for approved NRX-101 and NRX-100 products.
Strategia
NRx is building a two-part model: advance NMDA-targeted drug candidates through FDA review while also creating a clinic-based care platform through HOPE. The strategy combines proprietary therapeutics, interventional psychiatry services, and clinic acquisitions to create both near-term service revenue and longer-term product commercialization. Partnerships with TMS providers and clinic operators are intended to expand patient access and support outcomes-driven care delivery.
FDA approval is the main path to product commercialization and value creation.
Clinic ownership creates service revenue and a channel for treatment protocols.
Clinical data and protocol standardization can support physician adoption and differentiation.
Maantiede
NRx is headquartered in the United States and its reported business activity is centered on U.S. drug development, regulatory filings, and clinic operations. The company’s clinical care footprint is being built through U.S. acquisitions and partnerships, including Florida-based activity mentioned in the filings. Geography matters because FDA regulation, clinic licensing, and patient access are all U.S.-specific and shape how the business can scale.
Riskit
NRx depends on successful FDA review, clinical validation, and execution of acquisitions and clinic integrations, all of which can materially affect the business. As a clinical-stage biotech with a growing care-delivery platform, it also faces financing, regulatory, reimbursement, and operational risks typical of early commercial healthcare models. The company’s reported risks emphasize transaction uncertainty, integration challenges, and the possibility that expected benefits from acquisitions may not materialize.
HOPE growth depends on closing and integrating clinic acquisitions and partnerships.
Kohdistuu: HOPE Therapeutics
NRX-101 and NRX-100 require FDA acceptance and approval before broad commercialization.
Kohdistuu: Drug pipeline
Psychiatric drug development depends on trial outcomes and tolerability in high-risk patients.
Clinic services and TMS-based protocols require payer support and provider acceptance.
Kohdistuu: Interventional psychiatry services
Kirjanpito
Harkinnanvaraiset erätFair value estimates drive non-cash expense and can materially affect reported losses.
Vaikutus: Employee and director awards
Changes in share price and volatility assumptions can create large non-cash gains or losses.
Vaikutus: Equity-linked instruments
Monte Carlo-based valuation depends on volatility, default probability, and term assumptions.
Vaikutus: Liability measurement
Clinic acquisitions may create goodwill or intangibles that require future impairment testing.
Vaikutus: HOPE acquisitions
NRX-101 licensing terms can create future cash obligations and expense recognition timing issues.
Vaikutus: NRX-101 commercialization
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Vanda Pharmaceuticals Inc.
VNDA · Pharmaceutical Preparations
CNBX Pharmaceuticals Inc.
CNBX · Pharmaceutical Preparations
Addex Therapeutics Ltd.
ADXN · Pharmaceutical Preparations
Päivitetty: 24.9.2026